Alnylam Pharmaceuticals Ownership | Who Owns Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals Ownership Summary
Alnylam Pharmaceuticals is owned by 100.50% institutional investors, 4.09% insiders. Capital world investors is the largest institutional shareholder, holding 12.91% of ALNY shares. Capital Group Growth Fnd of Amer Comp is the top mutual fund, with 8.19% of its assets in Alnylam Pharmaceuticals shares.
ALNY Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Alnylam Pharmaceuticals | 100.50% | 4.09% | -4.59% |
| Sector | Healthcare Stocks | 57.39% | 9.93% | 32.68% |
| Industry | Biotech Stocks | 68.48% | 9.65% | 21.87% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Capital world investors | 16.60M | 12.91% | $3.91B |
| Fmr | 13.49M | 10.49% | $3.17B |
| Vanguard group | 12.73M | 9.90% | $3.00B |
| Blackrock funding, inc. /de | 9.89M | 7.69% | $2.33B |
| Blackrock | 9.55M | 7.57% | $2.32B |
| Capital research global investors | 6.97M | 5.42% | $1.64B |
| Regeneron pharmaceuticals | 4.44M | 3.46% | $1.05B |
| T. rowe price investment management | 4.38M | 3.41% | $1.03B |
| Wellington management group llp | 4.20M | 3.26% | $987.51M |
| Baillie gifford | 4.04M | 3.14% | $950.71M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Regeneron pharmaceuticals | 4.44M | 95.54% | $1.05B |
| Bridger management | 41.18K | 5.21% | $9.69M |
| Palo alto investors lp | 140.68K | 5.13% | $33.10M |
| Artia global partners lp | 56.40K | 4.74% | $13.27M |
| Eagle health investments lp | 76.26K | 4.40% | $17.94M |
| Bellevue group | 770.27K | 3.49% | $181.25M |
| Beck bode | 56.02K | 2.41% | $13.18M |
| Rock springs capital management lp | 256.20K | 2.30% | $60.29M |
| 683 capital management | 122.90K | 2.26% | $29.86M |
| Casdin capital | 140.00K | 2.19% | $32.94M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Regeneron pharmaceuticals | 4.44M | 95.54% | 4.44M |
| Norges bank | 2.46M | 0.08% | 2.46M |
| Capital research global investors | 6.97M | 0.34% | 1.72M |
| T. rowe price investment management | 4.38M | 0.64% | 1.25M |
| Blackrock | 9.55M | 0.05% | 522.66K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Capital investors | 1.42M | 0.06% | -2.55M |
| Fmr | 13.49M | 0.19% | -1.19M |
| Baillie gifford | 4.04M | 0.73% | -846.74K |
| Wellington management group llp | 4.20M | 0.18% | -756.72K |
| Logos global management lp | - | - | -500.00K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Regeneron pharmaceuticals | 4.44M | 95.54% | 4.44M | $1.05B |
| Norges bank | 2.46M | 0.08% | 2.46M | $577.94M |
| Raymond james financial | 277.49K | 0.02% | 277.49K | $65.30M |
| Jennison associates | 259.91K | 0.04% | 259.91K | $61.16M |
| Westfield capital management co lp | 216.13K | 0.22% | 216.13K | $50.86M |
Sold Out
| Holder | Change |
|---|---|
| Harbor investment advisory | -1.00 |
| Johnson financial group | -1.00 |
| Financial gravity asset management | -1.00 |
| Salem investment counselors | -1.00 |
| Capital analysts | -2.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | 603 | -0.33% | 129,230,860 | 5.02% | 100 | 1.10% | 315 | -2.78% | 183 | 6.40% |
| Sep 30, 2024 | 599 | 4.17% | 123,006,457 | 2.58% | 95 | 1.07% | 320 | 10.73% | 170 | 4.94% |
| Jun 30, 2024 | 571 | 3.25% | 119,905,127 | 6.57% | 95 | 1.19% | 286 | 4.38% | 162 | 3.18% |
| Mar 31, 2024 | 553 | 3.56% | 112,509,382 | -3.80% | 89 | 1.02% | 274 | 3.40% | 157 | 1.95% |
| Dec 31, 2023 | 534 | 8.32% | 116,949,479 | 0.55% | 93 | 1.09% | 265 | 28.02% | 154 | -7.23% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Capital Group Growth Fnd of Amer Comp | 10.57M | 8.19% | -274.74K |
| American Funds Growth Fund of Amer A | 10.57M | 8.19% | -274.74K |
| Vanguard US Total Market Shares ETF | 4.07M | 3.15% | 54.28K |
| Vanguard Total Stock Mkt Idx Inv | 4.06M | 3.14% | 10.70K |
| Capital Group AMCAP Composite | 3.73M | 2.89% | 658.62K |
| VA CollegeAmerica Amcap 529A | 3.73M | 2.89% | 658.62K |
| American Funds AMCAP A | 3.73M | 2.89% | 658.62K |
| Vanguard Health Care Inv | 3.52M | 2.73% | -497.08K |
| Capital Group New Perspective Comp | 2.93M | 2.27% | -778.02K |
| American Funds New Perspective A | 2.93M | 2.27% | -778.02K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Mar 21, 2025 | Garg Pushkal | CMO & EVP Dev & Med Affairs | Sell | $1.23M |
| Mar 24, 2025 | Garg Pushkal | CMO & EVP Dev & Med Affairs | Sell | $1.63M |
| Mar 24, 2025 | PYOTT DAVID E I | - | Sell | $2.22M |
| Mar 03, 2025 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | $27.22K |
| Mar 03, 2025 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | $54.51K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q1 | - | 152 |
| 2024 Q4 | - | 36 |
| 2024 Q3 | - | 16 |
| 2024 Q2 | - | 67 |
| 2024 Q1 | - | 46 |
ALNY Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools